Evidence map›Paper›PMID 40259161›Full record

ReviewBrain tumor pathology2025

The function of chaperones in the radioresistance of glioblastoma: a new insight into the current knowledge.

Reza Arefnezhd, Amir Modarresi Chahardehi, Amirmasoud Asadi, Mahammad Mehdi Shadravan, Abbas Shariati, Aryan Rezaee, Mehrsa Radmanesh, Mohammadreza Nazarian, Maryam Helfi, Mohammad Saeed Soleimani Meigoli and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Brain tumor pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Reza Arefnezhd *Coenzyme R Research Institute, Tehran, Iran.
Amir Modarresi Chahardehi *Coenzyme R Research Institute, Tehran, Iran.
Amirmasoud Asadi *Department of Medical Physics, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Mahammad Mehdi ShadravanStudent Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abbas ShariatiCoenzyme R Research Institute, Tehran, Iran.
Aryan RezaeeStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mehrsa RadmaneshFaculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Mohammadreza NazarianStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Maryam HelfiDepartment of Medical Physics, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Mohammad Saeed Soleimani MeigoliFaculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Hossein MotedayyenAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. hmotedayyen@gmail.com.
Fatemeh Rezaei-TazangiDepartment of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran. f.rezaei67@yahoo.com.ORCID http://orcid.org/0000-0003-1402-6482
Marziye Ranjbar TavakoliPharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy remains a cornerstone of brain tumor treatment; however, its effectiveness is frequently undermined by the development of radioresistance. This review highlights the pivotal role of molecular chaperones in promoting radioresistance and explores the potential to increase radioresistance in brain cancers, particularly glioblastoma (GBM). Among chaperones, heat shock proteins (HSPs), such as HSP70 and HSP90, have been identified as key contributors to radioresistance, acting through mechanisms that include the maintenance of protein homeostasis, enhancement of DNA repair processes, and protection of cancer stem cells. Specifically, HSP70 and HSP90 are crucial in stabilizing oncogenic proteins and preventing apoptosis, thus enabling tumor survival during radiotherapy. Also, HSP27 and GRP78 are involved in the radioresistance of brain tumors mainly by suppressing cell death and enhancing tumor stem cell propagation. Emerging evidence also suggests that targeting these chaperones, in combination with radiotherapy, can enhance tumor radiosensitivity, offering promising therapeutic strategies. Recent studies have revealed novel aspects of chaperone-mediated autophagy and interaction with non-coding RNAs, providing deeper insights into the molecular mechanisms underlying radioresistance. This review also addresses the potential of combining chaperone-targeted therapies, such as HSP90 inhibitors, with radiotherapy to overcome resistance. Ultimately, understanding these mechanisms may pave the way for innovative clinical applications and personalized therapeutic approaches in brain tumor treatment.

Indexed as

Brain NeoplasmsGlioblastomaMolecular ChaperonesRadiation ToleranceAnimalsApoptosisAutophagyEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsHumansNeoplastic Stem CellsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsHSPA5 protein, humanMolecular ChaperonesBrain tumorsChaperoneGlioblastomaHeat shock proteinsRadioresistance

Identifiers

PMID40259161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.